Polysorbate 80 blocked a peripheral sodium channel,Na v 1.7,and reduced neuronal excitability

Abstract

Polysorbate 80 is a non-ionic detergent derived from polyethoxylated sorbitan and oleic acid. It is widely used in pharmaceuticals, foods, and cosmetics as an emulsifier. Na_v1.7 is a peripheral sodium channel that is highly expressed in sympathetic and sensory neurons, and it plays a critical role in determining the threshold of action potentials (APs). We found that 10 μg/mL polysorbate 80 either abolished APs or increased the threshold of the APs of dorsal root ganglions. We thus investigated whether polysorbate 80 inhibits Na_v1.7 sodium current using a whole-cell patch-clamp recording technique. Polysorbate 80 decreased the Na_v1.7 current in a concentration-dependent manner with a half-maximal inhibitory concentration (IC₅₀) of 250.4 μg/mL at a holding potential of −120 mV. However, the IC₅₀ was 1.1 μg/mL at a holding potential of −90 mV and was estimated to be 0.9 μg/mL at the resting potentials of neurons, where most channels are inactivated. The activation rate and the voltage dependency of activation of Na_v1.7 were not changed by polysorbate 80. However, polysorbate 80 caused hyperpolarizing shifts in the voltage dependency of the steady-state fast inactivation curve. The blocking of Na_v1.7 currents by polysorbate 80 was not reversible at a holding potential of −90 mV but was completely reversible at −120 mV, where the channels were mostly in the closed state. Polysorbate 80 also slowed recovery from inactivation and induced robust use-dependent inhibition, indicating that it is likely to bind to and stabilize the inactivated state. Our results indicate that polysorbate 80 inhibits Na_v1.7 current in concentration-, state-, and use-dependent manners when used even below commercial concentrations. This suggests that polysorbate 80 may be helpful in pain medicine as an excipient. In addition, in vitro experiments using polysorbate 80 with neurons should be conducted with caution.

Keywords

Tween 80 polysorbate 80 voltage-gated sodium channel excipient emulsifier

Introduction

Polysorbate 80 (polyoxyethylene sorbitan monooleate), also known as Tween 80, is a synthetic non-ionic surfactant that is widely and commercially used in biochemical applications, such as solubilizing proteins and emulsifying and dispersing substances in medical and food products.^1–4 Polysorbate 80 inhibits aggregation and minimizes surface absorption at the air-water interface and upon dilution into intravenous fluids. The concentration of polysorbate 80 as an excipient ranges from 0.01–2 mg/mL, corresponding to 10–2000 ppm.⁴ Although polysorbate 80 has been associated with several systemic reactions, such as hypersensitivity, nonallergic anaphylaxis and rash, and injection- and infusion-site adverse events such as pain, erythema, and thrombophlebitis,^5–9 whether polysorbate 80 affects the excitability or ion channel activity of neurons has not been investigated.

Voltage-gated sodium channels are essential for electrogenesis in excitable cells. In humans, they exist as nine sodium channel isoforms and display different kinetics and voltage-dependent properties, and their different deployment in different types of neurons endows these cells with distinct firing properties.¹⁰ Among these channels, Na_v1.7, Na_v1.8, and Na_v1.9 are preferentially and selectively expressed in the peripheral nervous system, particularly nociceptive dorsal root ganglions (DRG).^11,12 The expression of Na_v1.7 was first identified in sympathetic and somatosensory ganglion neurons and has since been found in myenteric neurons, olfactory sensory neurons, visceral sensory neurons, and smooth myocytes.¹³ Activated by small, slow ramp stimuli, Na_v1.7 amplifies generator potentials toward the action potential (AP) threshold and acts as a threshold channel in nociceptive neurons. Na_v1.8 generates slow TTX-resistance sodium currents¹¹ and carries the largest inward charge during the upstroke of the AP.^14,15 Na_v1.9 produces persistent sodium current in DRG neurons and appears to modulate resting membrane potential.¹⁶

We unexpectedly found that APs in many small-diameter nociceptive DRG neurons disappeared after perfusion with 10 μg/mL polysorbate 80 as a control condition for evaluating drug efficacy. As polysorbate is a common excipient used in therapeutic protein formulas, we investigated how polysorbate 80 at the commercially used concentration could diminish neuronal excitability.

Materials and methods

Primary dorsal root ganglions culture

Adult male Sprague Dawley rats (6-7 weeks old) were used according to the Catholic University of Korea Institutional Animal Care and Use Committee guidelines. L4-L6 DRG neurons were isolated and incubated in a complete saline solution (in mM: 137 NaCl, 5.3 KCl, 1 MgCl₂, 25 D-sorbitol, 3 CaCl₂, and 10 HEPES at a final pH of 7.2, adjusted with NaOH), as described previously by Rizzo et al.¹⁷ and enzymatically digested with collagenase A (1 mg/mL; Roche, Indianapolis, IN) and then with collagenase D (1 mg/mL; Roche) and papain (30 U/mL; Worthington, Lakewood, NJ) for 20 min at 37°C, and then gently centrifuged (900 rpm for 3 min). Pellets were triturated in 1:1 DMEM/F-12 media (Thermo Fisher Scientific, Waltham, MA) with 10% FBS and 100X Penicillin-Streptomycin (Thermo Fisher Scientific) containing bovine serum albumin (1.5 mg/mL; Sigma, S Louis, MO) and trypsin inhibitor (1.5 mg/mL; Sigma). Cells were plated on 12 mm Poly-D-Lysine/Laminin coated glass coverslips (Corning, Corning, NY). The electrophysiological recording was started after 2 hours when DRG cells were stabilized and attached well on coverslips.

Cell culture and preparation of Na_v1.7

Human embryonic kidney (HEK293) cells stably expressing human Na_v1.7 purchased from Millipore (CYL3011; Billerica, MA) were cultured in Dulbecco’s modified Eagle’s medium (Thermo Fisher Scientific) supplemented with 10% fetal bovine serum (Thermo Fisher Scientific) in an incubator. Cells were maintained in a humidified atmosphere at 37°C with 5% CO₂-enriched air. Cells were passaged every 2-3 days by brief trypsinization. Cells treated with 0.25% trypsin-EDTA (Thermo Fisher Scientific) were plated on 12 mm glass coverslips (Fisher Scientific, Pittsburgh, PA) in 35 mm cell culture dishes. The electrophysiological recording was conducted after 24 hours.

Whole-cell patch-clamp recordings

Whole-cell patch-clamp recordings were performed with Multiclamp 700B amplifiers (Molecular Devices, Sunnyvale, CA) for the current-clamp experiments at room temperature (22–25°C). The internal solution contained (in mM) 140 KCl, 1 EGTA, 10 NaCl, 10 HEPES, and 2 ATP-Mg at a final pH of 7.3 using KOH (osmolarity was adjusted to 310 mOsmol/L with sucrose). The external solution contained (in mM) 140 NaCl, 3 KCl, 1 MgCl₂, 1 CaCl₂, 10 glucose, and 10 HEPES at a final pH of 7.3 using NaOH (osmolarity was adjusted to 320 mOsmol/L with sucrose). Small-diameter DRG neurons (≤30 μm in diameter) were selected as most small-diameter neurons are known to be nociceptive neurons.

Voltage-clamp recordings of Na_v1.7 were obtained using an Axopatch 200B amplifier (Molecular Devices) using the following solutions: the internal solution contained (in mM) 140 CsF, 10 NaCl, 1 EGTA, and 10 HEPES at a final pH of 7.3 using CsOH (osmolarity was adjusted with sucrose); the external solution for the Na_v1.7 sodium currents contained (in mM) 140 NaCl, 3 KCl, 1 MgCl₂, 1 CaCl₂, and 10 HEPES at a final pH of 7.3 using NaOH (osmolarity was adjusted with sucrose).

Pipettes were pulled from soft glass capillaries (World Precision Instruments, Sarasota, FL) using a programmable horizontal microelectrode puller (Sutter Instrument Co., Novato, CA) and were polished using a microforge. The resistances of pipettes were 1.5–2.0 MΩ and 0.9–1.2 MΩ when filled with the internal solution for current-clamp and voltage-clamp recordings, respectively. During the perfusion of the external bath solution, pipettes were wrapped with parafilm to reduce the capacitance. The coverslips containing adherent cells were on the glass bottom of the chamber and maintained at 22°C using a temperature controller (Dagan Corporation, Minneapolis, MN). Cells were not considered for analysis if they had a high leakage current (holding current > 500 pA at a holding potential of −90 mV) or an access resistance greater than 2.0 MΩ.

The current-clamp recordings were started when the resting membrane potential was stabilized, and then the cells were continuously perfused with either the external solution or 10 μg/mL polysorbate 80 for 5 min before collecting data. Voltage-clamp data were recorded after 7 min perfusion with either the external solution or 10 μg/mL polysorbate 80. The currents were filtered at 5 kHz and the sampling rate was 100 kHz. Voltage errors were minimized using a 90% series resistance compensation in all recordings. Voltage-clamp pulses and data acquisition were controlled using pClamp 10.7 Software (Molecular Devices) and Digidata 1440A acquisition board (Molecular Devices).

Compound application

Tween™ 80 Surfact-Amps™ Detergent Solution (10% (w/v) solution) was purchased from Thermo Fisher Scientific and diluted with the standard external bath solution to obtain the desired concentration. Polysorbate 80 solutions were made fresh before patch-clamp recordings and applied through a gravity-driven system with a perfusion pencil (Automate Scientific, Berkeley, CA), allowing rapid perfusion of the recording chamber. During the recording, the cells were continuously perfused with the test solution.

Protocols and data analysis

For current-clamp recordings, APs were elicited by three types of current injections: 500 ms long-step current, 50 ms short-step current, and 4 pA/ms ramp current. Long-step current injections were used to measure the current threshold and the number of APs at 500 pA current injection. Short-step current injections were used to analyze the shape of APs and the voltage threshold.

For voltage-clamp recordings, the concentration-dependent inhibition of currents by polysorbate 80 was elicited using a 100 ms depolarizing pulse of 0 mV from various holding potentials (−120, −110, −105, −100, and −90 mV) for Na_v1.7 at 5 s intervals. Data were best fitted to the logistic equation Y = 1/[1 + IC₅₀/D]^p using OriginPro Software, where IC₅₀ is the 50% inhibition of polysorbate 80 concentration, D is the concentration of polysorbate 80, and p is the Hill coefficient.

Whole-cell Na_v1.7 currents were elicited by using a 50 ms depolarizing pulse at potentials between −70 mV and +40 mV in steps of +5 mV with a holding potential of −90 mV at 5 s intervals. Peak currents at each voltage step were normalized into conductance (G) according to the relationship V = IR, I = G(V/V_rev), where V_rev is the reversal potential of sodium current. This was used to analyze the voltage dependency of activation. Steady-state inactivation was determined using a test pulse of +10 mV following 500 ms conditioning pulses between −170 mV and −30 mV with a holding potential of −90 mV. The voltage-dependent activation curves and steady-state inactivation curves were fitted by the Boltzman equation: G/Gmax (or I/Imax) = 1/[1 + exp(V_m−V_1/2)/k]], where V_m is the test (or conditioning) potential, V_1/2 is the midpoint of activation (or inactivation) curve, and k is the slope factor of the curve. Recovery from inactivation was measured at each peak current in response to a step of 0 mV, which was preceded by a 50 ms pulse of 0 mV and a recovery period with variable durations and potentials. Use-dependent inhibition was determined using 20 repetitive 50 ms depolarizing pulses of −10 mV with a holding potential of −90 mV at 0.5, 3, and 10 Hz.

Statistics

Student’s t-tests were used for statistical analysis. All averaged and normalized data are presented as the mean ± SE. A value of p < 0.05 was considered statistically significant. Data acquisition and analysis were performed using pClamp 10.7 software (Molecular Devices) and OriginPro 8.5 Software (Origin Lab Corp., Northampton, MA).

Results

Alteration of action potential characteristics by polysorbate 80 in rat dorsal root ganglions neurons

As polysorbate 80 is one of the most common surfactants for many drug formations, we tested whether polysorbate 80 itself affects the excitability of DRG neurons. The average size of DRG neurons was approximately 25.62 ± 0.24 μm and the initial characteristics of current-clamp recordings, such as membrane capacitance, input resistance, and resting membrane potential, were not significantly different between the groups before perfusion with the external solution, regardless of the presence of 10 μg/mL polysorbate 80 (Table 1). After 5 minutes of perfusion with either the control solution or polysorbate 80, APs were elicited from 0 to 500 pA step current injection for 500 ms from a resting membrane potential (Figure 1(a)). The current threshold (the minimum injection current that generates AP) was slightly higher in the presence of polysorbate 80 than with the control solution when neurons generated an AP, but this was not statistically significant. However, three out of seven neurons after perfusion with polysorbate 80 did not produce any APs even in 500 pA injection current, while all neurons perfused with the control solution generated APs (n = 7). Additionally, the voltage threshold was higher in the presence of polysorbate 80 than with the control, suggesting that stronger stimulation is required to evoke APs in the presence of polysorbate 80. Overall, the number of APs (>0 mV) in the presence of polysorbate 80 stimulated by 500 pA current injection was decreased compared to the control experiment.

Table 1.

Properties of AP in rat DRG neurons in the absence (n = 7) and presence (n = 7) of 10 μg/mL polysorbate 80.

	Control	Polysorbate 80
Recording condition
Size (μm)	25.52 ± 0.44	25.71 ± 0.20
Membrane capacitance (pF)	24.68 ± 0.98	23.96 ± 0.93
Input resistance (GΩ)	0.51 ± 0.20	0.51 ± 0.22
RMP (mV)	−63.07 ± 1.98	−59.50 ± 3.13
Long (500 ms) step current injection
Current threshold (pA)	164.29 ± 20.45	280.00 ± 60.28
Voltage threshold (mV)	−33.55 ± 0.66	−15.83 ± 5.05^a
No. of APs at 500 pA (>0 mV)	6.00 ± 1.23	1.71 ± 0.71^a
Short (0.5 ms) step current injection
Current threshold (pA)	535.71 ± 32.58	670.00 ± 65.03
Voltage threshold (mV)	−28.18 ± 0.67	−15.20 ± 4.51^a
AP peak (mV)	41.69 ± 2.38	21.68 ± 7.91^a
AP duration (ms)	1.95 ± 0.23	1.38 ± 0.28
Ramp (4 pA/ms) current injection
No. of APs (>0 mV)	6.43 ± 0.97	2.57 ± 1.02^a
Time to 1^st peak (ms)	56.58 ± 8.12	264.06 ± 84.50^a

Values are means ± SE.

^ap < 0.05 relative to control.

Figure 1.

APs recorded by the current clamp experiments in the absence (left) and presence (right) of 10 μg/mL polysorbate 80. AP characteristics are summarized in Table 1. Representative traces for 500 pA of 500 ms long step current (a), 0.5 ms short step current (b), and 4 pA/ms ramp current (c).

To identify whether polysorbate 80 affects the characteristics of AP shape (Figure 1(b)), we injected a short (0.5 ms) minimum suprathreshold current to generate a single AP while also minimizing the effect of the injected stimulus current. The current threshold was not significantly changed and the voltage threshold was increased by polysorbate 80, similar to those by long current injection. While the duration of AP was not changed by polysorbate 80, the peak amplitude of AP was significantly lowered, indicating that polysorbate 80 may primarily inhibit sodium channels but not potassium channels.

We also analyzed the APs generated by slow ramp current injections, which mimic physiological stimulation (Figure 1(c)). Due to the adaptation of APs, we only counted overshooting APs (AP peaks >0 mV). When polysorbate 80 was present, the number of APs significantly decreased, and it took longer to generate the first AP in instances where they were produced. Moreover, the cells which did not produce any APs by long injection current, never showed any AP, even by the most robust ramp current injection. Therefore, these results suggest that polysorbate 80 decreases neuronal excitability by increasing current and voltage thresholds.

Inhibition of Na_v1.7 currents by polysorbate 80 is concentration-dependent and increases at more depolarized holding potentials

Na_v1.7 is known as a threshold sodium channel for pain perception in human beings.^11,18 Therefore, we investigated whether polysorbate 80 inhibits human Na_v1.7 current. Polysorbate 80 decreased peak currents of Na_v1.7 in a concentration-dependent manner at a holding potential of −120 mV with a half-maximal inhibition concentration (IC₅₀) of 250.4 ± 61.3 μg/mL and a Hill coefficient of 0.49 ± 0.04 (Figure 2(a), n = 7). As the IC₅₀ was higher than we expected and our previous report¹⁹ showed that some sodium channel blockers produced a potent blocking effect at the depolarized membrane potentials where sodium channels exist at more inactivated state, we also tested at a holding potential of −90 mV (Figure 2(b)). The IC₅₀ for polysorbate 80 was 1.1 ± 0.1 μg/mL (n = 8) and the Hill coefficient was 1.02 ± 0.04. Interestingly, depolarized membrane potential not only increased the efficacy of polysorbate 80 but also brought the Hill coefficiency close to 1. To estimate the IC₅₀ at the most depolarized holding potential, we obtained IC₅₀ at various membrane potentials. The IC₅₀ at holding potentials of −110, −105, and −100 mV were 70.8 ± 14.2 (n = 10), 17.2 ± 1.9 (n = 5), and 4.3 ± 0.5 (n = 7), respectively (Figure 2(c)). The Hill coefficients at holding potentials of −110, −105, and −100 mV were 0.59 ± 0.02, 0.70 ± 0.02, and 0.82 ± 0.06, respectively. When the holding potential was closer to the average resting membrane potential of DRG neurons (i.e. approximately −60 mV, Table 1), the value of IC₅₀ was lower, and the slope of the graph was steeper. We assumed that polysorbate 80 may bind with Na_v1.7 at a 1:1 ratio with a holding potential of −90 mV, but when the holding potential is hyperpolarized and closer to the resting state for ion channels, there are more binding sites which also show negative cooperativity. Based on a previous report,²⁰ we measured the maximal and minimal IC₅₀ of polysorbate 80 to the closed state at rest (1/K_r) and the inactivated state (1/K_i). Means of IC₅₀ values calculated from Figure 2(c) at each holding potential were plotted and fitted with K_app = 1/[h/K_r + (1 − h)/K_i)], where h and 1-h are the fraction of channels in the resting and inactivated states, respectively. The IC₅₀ values for K_r and K_i were 207.40 μg/mL and 0.95 μg/mL, indicating that IC₅₀ values at the resting membrane potentials were approximately 1 μg/mL.

Figure 2.

Concentration- and voltage-dependence of polysorbate 80. Representative whole-cell Na_v1.7 currents in the absence and presence of polysorbate 80 at holding potentials of −120 mV (a) and −90 mV (b). (c) The normalized peaks of Na_v1.7 currents are plotted as a function of polysorbate 80 concentration. Dose-response curves at holding potentials of −120 mV (■, n = 8), −110 mV (□, n = 7), −105 mV (●, n = 5), −100 mV (○, n = 10), and −90 mV (▲, n = 7) were fitted with a logistic equation. (d) The values of IC₅₀ were calculated from Figure 2(c); the fitted line is the best fit to the equation K_app = 1/[h/K_r + (1 − h)/K_i)] where h and 1 − h are the fractions of channels in the resting and inactivated states, respectively.

Polysorbate 80 has a robust binding affinity in the inactivated state of Na_v1.7

We tested whether the effects of polysorbate 80 on Na_v1.7 were reversible. To normalize the blocking effect of polysorbate 80, Na_v1.7 currents continuously perfused with the control solution were initially recorded at a holding potential of −120 mV to measure the maximal peak current (Figure 3(a), ■) and then changed to a holding potential of −90 mV (★). After stabilizing the sodium current at a holding potential of −90 mV, 10 μg/mL polysorbate 80 was applied until the current reduction was stable in at least three consequent traces. The sodium current was inhibited by 82.9 ± 4.3% (n = 4) of peak current (•) with two exponential phases. A double exponential function well fitted the fast and slow components of inhibition, of which the time constants were 19.0 ± 14.1 and 120.2 ± 31.2 s, respectively. The block of Na_v1.7 currents was partially recovered after washout with a time constant of 28.9 ± 1.6 s at a holding potential of −90 mV (▲). However, the time constant was much faster (3.8 ± 0.4 s) when the holding potential was changed to −120 mV (◆), and 94.1 ± 0.4% of currents were recovered. These results indicate that polysorbate 80 preferentially binds to the inactivated state of Na_v1.7 and readily dissociates from the resting state of it.

Figure 3.

Reversible inhibition of Na_v1.7 currents by polysorbate 80. (a) Time course of Na_v1.7 current inhibition by 10 μg/mL polysorbate 80 at a holding potential of −90 mV (●) after applying the same test pulse from holding potentials of −120 mV (■) and −90 mV (★) in the absence of polysorbate 80 and washout effect at holding potentials of −90 mV (▲) and −120 mV (◆). (b) representative Na_v1.7 current traces for blocking and washout by polysorbate 80.

Polysorbate 80 hyperpolarized the voltage-dependency of steady-state fast inactivation of Na_v1.7

We investigated the effect of polysorbate 80 on the voltage dependence of activation and steady-state fast inactivation. As the membrane potential of neuronal cells is approximately −60 mV, we used 1 μg/mL polysorbate 80 at a holding potential of −90 mV. Figure 4(a) shows representative traces of Na_v1.7 in the absence (top) and presence (bottom) of 1 μg/mL polysorbate 80. When the voltage-dependent activation curves (Figure 4(b)) were fitted to the Boltzmann distribution equation, the midpoint of activation (V_1/2) and slope (k) values were −26.88 ± 0.94 mV and 6.51 ± 0.09 mV in the absence of polysorbate 80 (n = 9), respectively, and −26.77 ± 0.75 mV and 6.54 ± 0.28 mV in the presence of 1 μg/mL polysorbate 80 (n = 11), respectively. Therefore, the voltage dependency of the activation was not changed by polysorbate 80. We also examined the rates of activation (Figure 4(c)) and inactivation (Figure 4(d)) kinetics, indicating closed-to-open and open-to-inactivated transitions, respectively. At all test potentials, activation and inactivation kinetics were similar in the absence and presence of polysorbate 80. Contrary to the voltage-dependency of activation, the voltage-dependency of steady-state fast inactivation was more hyperpolarized than in the absence of polysorbate 80 (Figure 4(e)). The value of V_1/2 in the presence of 1 μg/mL polysorbate 80 (−100.66 ± 3.06 mV) was significantly more hyperpolarized than in the absence of polysorbate 80 (−80.72 ± 0.93 mV). In addition, the k of the steady-state fast inactivation curve in the presence of polysorbate 80 (10.41 ± 0.29 mV) was shallower than in its absence (5.19 ± 0.18 mV).

Figure 4.

Effect of polysorbate 80 on channel kinetics at a holding potential of −90 mV. Whole-cell Na_v1.7 currents were elicited by a 50 ms depolarizing pulse to potentials between −70 and +40 mV in steps of +5 mV at 5 s intervals. (a) The representative whole-cell Na_v1.7 channel current trace in the absence (upper) and presence (lower) of 1 μg/mL polysorbate 80. (b) The activation curves were fitted to the Boltzmann distribution equation under control conditions (□, n = 9) and in the presence of 1 μg/mL polysorbate 80 (●, n = 11). Time-to-peak (c) and inactivation kinetics (d) as a function of test potentials in control conditions (□, n = 9) and in the presence of 1 μg/mL polysorbate 80 (●, n = 11). (e) Steady-state inactivation curves were determined using a test pulse at +10 mV after 500 ms conditioning pulses to voltages between −140 and −30 mV (for the control solution) and −170 and −30 mV (for 1 μg/mL polysorbate 80). Data were fitted to the Boltzmann distribution equation under control conditions (□, n = 7) and in the presence of 1 μg/mL polysorbate 80 (●, n = 7).

Na_v1.7 channels in the presence of polysorbate 80 recover slowly from inactivation

The high potency at depolarized holding potentials and the hyperpolarized shifts in the steady-state fast inactivation curve suggested that Na_v1.7 may slowly recover from inactivation and that channels remain inactivated for longer time periods. To confirm this hypothesis, we used a double-pulse protocol that measured the peak current in response to a step to 0 mV, which was preceded by a 50 ms pulse to 0 mV and a recovery period of 2.5, 5, 10, 20, 100, 500, 1,000, or 3000 ms at −90 mV (Figure 5(a)) or −120 mV (Figure 5(b)). The kinetics of recovery from inactivation in the absence of polysorbate 80 was fitted to a monoexponential function and the presence of polysorbate 80 was well fitted to a biexponential function. As expected, the time constant of recovery from fast (τ_fast) and slow (τ_slow) components of Na_v1.7 current in the presence of polysorbate 80 at −90 mV (τ_fast: 49.7 ± 12.1 s, τ_slow: 1201.1 ± 248.0 s, n = 5) and −120 mV (τ_fast: 46.4 ± 20.6 s, τ_slow: 717.5 ± 129.1 s, n = 6) were significantly slower than in the absence of polysorbate 80 (42.2 ± 5.1 s at −90 mV and 5.7 ± 0.6 s at −120 mV, n = 7). Interestingly, the recovery of the Na_v1.7 current reaches almost four times the normalized response of the control (Figure 5(b)), implying that long recovery periods at −120 mV induced the unbinding of polysorbate 80, which is shown in Figure 3, in addition to the recovery from inactivation of Na_v1.7.

Figure 5.

Recovery from inactivation and use-dependent inhibition of Na_v1.7. Recovery from inactivation was measured at peak current in response to a step to 0 mV, which was preceded by a 50 ms pulse at 0 mV and a recovery period with variable duration and potential. Recovery from inactivation at −90 mV (a) and −120 mV (b) under control conditions (□, n = 7) and in the presence of 1 μg/mL polysorbate 80 (●, n = 5–6). The data were fitted using monoexponential (control) and bi-exponential (polysorbate 80) functions. Use-dependent inhibition of Na_v1.7 at different frequencies in the presence and absence of 1 μg/mL polysorbate 80. Use-dependent inhibition was determined using 20 repetitive 50 ms depolarizing pulses to −10 mV with a holding potential of −90 mV at 0.5, 3, and 10 Hz. (c) Use-dependent fall-off of peak currents under control conditions (open symbols, n = 6–8) and in the presence of 1 μg/mL polysorbate 80 (closed symbols, n = 4–5) at 0.5 (squares), 3 (circles), and 10 (triangles) Hz. (d) The percentage decrease in the peak current between the 1^st and 20^th pulse of each frequency stimulation protocol under control conditions and in the presence of 1 μg/mL polysorbate 80 (*, p < 0.05).

Polysorbate 80 produced strong use-dependent inhibition of Na_v1.7

As polysorbate 80 slowed recovery from inactivation, we assumed that it might promote the accumulation of inactivated Na_v1.7 at higher frequencies of depolarization pulses in the presence of polysorbate 80. We investigated the use-dependent inhibition of polysorbate 80 at frequencies of 0.5, 3, and 10 Hz in the absence and presence of 1 μg/mL polysorbate 80 (Figure 5(c)). In the absence of polysorbate 80, the peak amplitude of Na_v1.7 was decreased by 6.2, 22.7, and 43.1% at 0.5, 3, and 10 Hz, respectively (Figure 5(d)). However, in the presence of polysorbate 80, the peak amplitude of Na_v1.7 decreased by 14.6, 66.7, and 91.6% at 0.5, 3, and 10 Hz, respectively. These results indicate that polysorbate 80 produced strong use-dependent inhibition in proportion to the stimulation frequency.

Discussion

Small molecule drugs have been developed as major therapeutics for nearly a century because most can be administered orally and can pass through cell membranes to reach intracellular targets.²¹ Recently, biological therapeutics such as antibodies and mRNA vaccines, including traditional vaccines, have been highlighted due to their high specificity, and many are now commercially available in the pharmaceutical market.^2,4,22 They are designed to engage biological targets by various modes of action, but need adjuvants, solubilizers, or stabilizers of emulsions to prevent surface adsorption while also stabilizing against protein aggregation. Polysorbate 80 is the most common surfactant used in antibody formulations and is widely used in pharmaceuticals, foods, and cosmetics as an emulsifier.^2,22 Its concentration for drug formulation ranges from 10–2000 μg/mL, while for antibody formulations, the contents must be higher than the critical micelle concentration, which is approximately 17 μg/mL.⁴ Therefore, most commercial contents of polysorbate 80 that require micelle formation must be higher than the IC₅₀ (0.9 μg/mL) we observed in this study (Figure 2).

Polysorbate 80 is a mixture of isomeric organic compounds composed of sorbitan derivatives containing one oleic acid (>58%) or other fatty acids.⁴ Oleic acid is an unsaturated fatty acid with one double bond and occurs naturally in animal and vegetable fats and oils. It has been reported that polyunsaturated fatty acids act on many voltage-gated ion channels.²³ Monounsaturated fatty acids such as oleic acid also act on voltage-gated sodium channels by reducing their current and hyperpolarizing the voltage dependency of steady-state inactivation,^23–26 which is similar to our findings. It has been reported that there are five binding sites of polyunsaturated fatty acids in ion channels.²³ Among these, site 1 is located in the intracellular cavity of sodium channels, and the binding of polyunsaturated fatty acids reduces the sodium current by inducing hyperpolarization of the steady-state inactivation curve. All other binding sites (site 2–5) are found in potassium or calcium channels, and the effects are not similar to our results. The Hill coefficiencies in this study were smaller than 1 at holding potentials lower than −100 mV, suggesting that the binding sites in the Na_v1.7 channel for polysorbate 80 are likely multiple and have negative cooperativity. This is unsurprising as polysorbate 80 is not a pure compound; thus, more than one unsaturated fatty acid residue of polysorbate 80 may bind to multiple sites and produce multiple blocking effects. The on-rate of blocking Na_v1.7 current by polysorbate 80 at a holding potential of −90 mV showed biphasic decay (Figure 3). However, the off-rate was fitted well by monoexponential functions individually at each holding potential, indicating that there are at least two binding sites: one in the closed state with a low affinity and the other in the inactivated state with high affinity. This hypothesis is consistent with a lower IC₅₀ at more depolarized holding potentials, suggesting that polysorbate 80 prefers to bind to the inactivated state and block Na_v1.7 current by stabilizing it. Taken together, the portion of unsaturated fatty acid in polysorbate 80 may be the primary component that accounts for our results. However, even though our hypothesis is well fitted with the reduction of nociceptive neuronal excitability, we cannot exclude the potential effect of polysorbate 80 on other nociceptive sodium channels such as Na_v1.8 and Na_v1.9. Among these, Na_v1.8 is especially known to contribute to most of the current underlying the depolarizing phase of the APs generated by nociceptive neurons,²⁷ which is why we can hypothesize that polysorbate 80 may also block this channel. However, it might be challenging to identify the blocking mechanism in detail for Na_v1.8 in a matter similar to our present study due to the difficulty of its heterologous expression.

In this study, although we found that polysorbate 80 has dramatic effects on the neuronal excitability of nociceptive DRG neurons at a widely-used concentration (10 μg/mL = 10 ppm = 0.001% = 7.63 μM), there is no obvious evidence yet that polysorbate 80 induced abnormalities of the sympathetic and somatosensory system.^6–9 It might be that the bulky hydrophilic sorbitan derivatives prevent rapid diffusion, not allowing for a systemic effect. However, polysorbate 80 kept isolated neurons from generating APs and directly blocked the threshold sodium channel of Na_v1.7 that is expressed in the HEK293 cell line in a concentration-, state-, and use-dependent manner. Thus, in vitro experiments using polysorbate 80 with neurons must be cautiously conducted. As Na_v1.7 is preferentially expressed in the sympathetic and somatosensory ganglion neurons and the channels are mostly inactivated at resting membrane potentials, polysorbate 80 might be useful as an excipient for pain medicine.

Footnotes

Author contributions

REK performed the electrophysiology, analyzed the data, and prepared the figures and tables. JSC designed the experiment and evaluated the data. REK and JSC wrote the manuscript.

Declaration of conflicting interests

The author(s) declared no potential conflicts of interest with respect to the research, authorship, and/or publication of this article.

Funding

The author(s) disclosed receipt of the following financial support for the research, authorship, and/or publication of this article: This study was supported by the Basic Science Research Program through the National Research Foundation of Korea (NRF) funded by the Ministry of Education (NRF-2016R1A2B4011333, NRF-2018R1A6A1A03025108).

ORCID iD

Jin-Sung Choi

References

Ema

Hara

Matsumoto

Hirata-Koizumi

Hirose

Kamata

. Evaluation of developmental neurotoxicity of polysorbate 80 in rats. Reprod Toxicol 2008; 25: 89–99. DOI: 10.1016/j.reprotox.2007.08.003

Strickley

Lambert

. A review of formulations of commercially available antibodies. J Pharm Sci 2021; 110: 2590–2608. DOI: 10.1016/j.xphs.2021.03.017

Greenhawt

Abrams

Shaker

Chu

Khan

Akin

Alqurashi

Arkwright

Baldwin

Ben-Shoshan

Bernstein

Bingemann

Blumchen

Byrne

Bognanni

Campbell

Chagla

Chan

Comberiati

Dribin

Ellis

Fleischer

Fox

Frischmeyer-Guerrerio

Gagnon

Grayson

Horner

Hourihane

Katelaris

Kim

Kelso

Lang

Ledford

Levin

Lieberman

Loh

Mack

Mazer

Mosnaim

Munblit

Mustafa

Nanda

Oppenheimer

Perrett

Ramsey

Rank

Robertson

Sheikh

Spergel

Stukus

Tang

MLK

Tracy

Turner

Whalen-Browne

Wallace

Wang

Waserman

Witry

Worm

Vander Leek

Golden

DBK

. The risk of allergic reaction to sars-cov-2 vaccines and recommended evaluation and management: a systematic review, meta-analysis, GRADE assessment, and international consensus approach. J Allergy Clin Immunol Pract 2021; 9: 3546–3567. DOI: 10.1016/j.jaip.2021.06.006

Kerwin

. Polysorbates 20 and 80 used in the formulation of protein biotherapeutics: Structure and degradation pathways. J Pharm Sci 2008; 97: 2924–2935. DOI: 10.1002/jps.21190

Schwartzberg

Navari

. Safety of polysorbate 80 in the oncology setting. Adv Ther 2018; 35: 754–767. DOI: 10.1007/s12325-018-0707-z

Steele

Limaye

Cleland

Chow

Suranyi

. Hypersensitivity reactions to the polysorbate contained in recombinant erythropoietin and darbepoietin. Nephrology (Carlton) 2005; 10: 317–320. DOI: 10.1111/j.1440-1797.2005.00389.x

Coors

Seybold

Merk

Mahler

. Polysorbate 80 in medical products and nonimmunologic anaphylactoid reactions. Ann Allergy Asthma Immunol 2005; 95: 593–599. DOI: 10.1016/S1081-1206(10)61024-1

Bergh

Magnusson

Nilsson

Karlberg

. Contact allergenic activity of tween 80 before and after air exposure. Contact Dermatitis 1997; 37: 9–18. DOI: 10.1111/j.1600-0536.1997.tb00368.x

ten Tije

Verweij

Loos

Sparreboom

. Pharmacological effects of formulation vehicles: Implications for cancer chemotherapy. Clin Pharmacokinet 2003; 42: 665–685. DOI: 10.2165/00003088-200342070-00005

10.

Catterall

Goldin

Waxman

. International union of pharmacology: XLVII. nomenclature and structure-function relationships of voltage-gated sodium channels. Pharmacol Rev 2005; 57: 397–409. DOI: 10.1124/pr.57.4.4

11.

Bennett

Clark

Huang

Waxman

Dib-Hajj

. The role of voltage-gated sodium channels in pain signaling. Physiol Rev 2019; 99: 1079–1151. DOI: 10.1152/physrev.00052.2017

12.

Hameed

. Na(v)1.7 and Na(v)1.8: role in the pathophysiology of pain. Mol Pain 2019; 15: 1744806919858801. DOI: 10.1177/1744806919858801

13.

Dib-Hajj

Yang

Black

Waxman

. The Na(V)1.7 sodium channel: from molecule to man. Nat Rev Neurosci 2013; 14: 49–62. DOI: 10.1038/nrn3404

14.

Renganathan

Cummins

Waxman

. Contribution of Na(v)1.8 sodium channels to action potential electrogenesis in DRG neurons. J Neurophysiol 2001; 86: 629–640. DOI: 10.1152/jn.2001.86.2.629

15.

Choi

Waxman

. Physiological interactions between Na(v)1.7 and Na(v)1.8 sodium channels: a computer simulation study. J Neurophysiol 2011; 106: 3173–3184. DOI: 10.1152/jn.00100.2011

16.

Dib-Hajj

Black

Waxman

. NaV1.9: A sodium channel linked to human pain. Nat Rev Neurosci 2015; 16: 511–519. DOI: 10.1038/nrn3977

17.

Rizzo

Kocsis

Waxman

. Slow sodium conductances of dorsal root ganglion neurons: Intraneuronal homogeneity and interneuronal heterogeneity. J Neurophysiol 1994; 72: 2796–2815. DOI: 10.1152/jn.1994.72.6.2796

18.

Emery

Luiz

Wood

. Nav1.7 and other voltage-gated sodium channels as drug targets for pain relief. Expert Opin Ther Targets 2016; 20: 975–983. DOI: 10.1517/14728222.2016.1162295

19.

Kim

Park

Hahn

Choi

. Norquetiapine blocks the human cardiac sodium channel Na(v)1.5 in a state-dependent manner. Eur J Pharmacol 2020; 885: 173532–20200901. DOI: 10.1016/j.ejphar.2020.173532

20.

McDonough

Bean

. Mibefradil inhibition of T-type calcium channels in cerebellar purkinje neurons. Mol Pharmacol 1998; 54: 1080–1087. DOI: 10.1124/mol.54.6.1080

21.

Chhabra

. Biological therapeutic modalities. In: Hasija

(ed), Translational biotechnology. Cambridge, MA, USA: Academic Press, 2021, pp. 137–164.

22.

Ascarateil

Dupuis

. Surfactants in vaccine adjuvants: Description and perspectives. Vaccine 2006; 24(Suppl 2): S2–S8385. DOI: 10.1016/j.vaccine.2005.01.134

23.

Elinder

Liin

. Actions and mechanisms of polyunsaturated fatty acids on voltage-gated ion channels. Front Physiol 2017; 8: 43. DOI: 10.3389/fphys.2017.00043

24.

Iida

Kishida

Imuta

Oonuma

Nagata

Hara

Iwasawa

Soma

Sato

Nagase

Nagai

Nakajima

. Acute and chronic effects of eicosapentaenoic acid on voltage-gated sodium channel expressed in cultured human bronchial smooth muscle cells. Biochem Biophys Res Commun 2005; 331: 1452–1459. DOI: 10.1016/j.bbrc.2005.04.062

25.

Hong

Kim

Shin

Lee

Park

Song

. Effects of free fatty acids on sodium currents in rat dorsal root ganglion neurons. Brain Res 2004; 1008: 81–91. DOI: 10.1016/j.brainres.2004.02.033

26.

Bendahhou

Cummins

Agnew

. Mechanism of modulation of the voltage-gated skeletal and cardiac muscle sodium channels by fatty acids. Am J Physiol 1997; 272: C592–C600. DOI: 10.1152/ajpcell.1997.272.2.C592

27.

Blair

Bean

. Roles of tetrodotoxin (TTX)-sensitive Na⁺ current, TTX-resistant Na⁺ current, and Ca²⁺ current in the action potentials of nociceptive sensory neurons. J Neurosci 2002; 22: 10277–10290. DOI: 10.1523/JNEUROSCI.22-23-10277.2002

Polysorbate 80 blocked a peripheral sodium channel,Na v 1.7,and reduced neuronal excitability

Abstract

Keywords

Introduction

Materials and methods

Primary dorsal root ganglions culture

Cell culture and preparation of Nav1.7

Whole-cell patch-clamp recordings

Compound application

Protocols and data analysis

Statistics

Results

Alteration of action potential characteristics by polysorbate 80 in rat dorsal root ganglions neurons

Inhibition of Nav1.7 currents by polysorbate 80 is concentration-dependent and increases at more depolarized holding potentials

Polysorbate 80 has a robust binding affinity in the inactivated state of Nav1.7

Polysorbate 80 hyperpolarized the voltage-dependency of steady-state fast inactivation of Nav1.7

Nav1.7 channels in the presence of polysorbate 80 recover slowly from inactivation

Polysorbate 80 produced strong use-dependent inhibition of Nav1.7

Discussion

Footnotes

Author contributions

Declaration of conflicting interests

Funding

ORCID iD

References

Cell culture and preparation of Na_v1.7

Inhibition of Na_v1.7 currents by polysorbate 80 is concentration-dependent and increases at more depolarized holding potentials

Polysorbate 80 has a robust binding affinity in the inactivated state of Na_v1.7

Polysorbate 80 hyperpolarized the voltage-dependency of steady-state fast inactivation of Na_v1.7

Na_v1.7 channels in the presence of polysorbate 80 recover slowly from inactivation

Polysorbate 80 produced strong use-dependent inhibition of Na_v1.7